General information about company |
|||
|---|---|---|---|
| Scrip Code | 541400 | ||
| NSE Symbol | ZIMLAB | ||
| MSEI Symbol | NOTLISTED | ||
| ISIN | INE518E01015 | ||
| Name of company | ZIM Laboratories Limited | ||
| Type of company | Main Board | ||
| Class of security | Equity | ||
| Date of start of financial year | 01-Apr-2025 | ||
| Date of end of financial year | 31-Mar-2026 | ||
| Date of board meeting when results were approved | 07-Aug-2025 | ||
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 31-Jul-2025 | ||
| Description of presentation currency | INR (in Actuals) | ||
| Reporting Type | Quarterly | ||
| Reporting Quarter | First quarter | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Whether results are audited or unaudited for the quarter ended | Unaudited | ||
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |||
| Segment Reporting | Single segment | ||
| Description of single segment | Pharmaceutical | ||
| Start date and time of board meeting | 07-Aug-2025 12:30:00 | ||
| End date and time of board meeting | 07-Aug-2025 19:00:00 | ||
| Whether cash flow statement is applicable on company | |||
| Type of cash flow statement | |||
| Declaration of unmodified opinion or statement on impact of audit qualification | Not applicable | ||
Financial Results Ind-AS |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Consolidated | |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | ||
| 1 | Income | ||
| Revenue from operations | 717561000 | ||
| Other income | 14763000 | ||
| Total income | 732324000 | ||
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 276173000 | |
| (b) | Purchases of stock-in-trade | 15930000 | |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | 7986000 | |
| (d) | Employee benefit expense | 146127000 | |
| (e) | Finance costs | 33035000 | |
| (f) | Depreciation, depletion and amortisation expense | 48635000 | |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 228758000 | 228758000 |
| Total other expenses | 228758000 | ||
| Total expenses | 756644000 | ||
| 3 | Total profit before exceptional items and tax | -24320000 | |
| 4 | Exceptional items | 0 | |
| 5 | Total profit before tax | -24320000 | |
| 6 | Tax expense | ||
| 7 | Current tax | 872000 | |
| 8 | Deferred tax | -6443000 | |
| 9 | Total tax expenses | -5571000 | |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | |
| 11 | Net Profit Loss for the period from continuing operations | -18749000 | |
| 12 | Profit (loss) from discontinued operations before tax | 0 | |
| 13 | Tax expense of discontinued operations | 0 | |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0 | |
| 16 | Total profit (loss) for period | -18749000 | |
| 17 | Other comprehensive income net of taxes | 4189000 | |
| 18 | Total Comprehensive Income for the period | -14560000 | |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | -18749000 | ||
| Total profit or loss, attributable to non-controlling interests | 0 | ||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | -14560000 | ||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | 0 | ||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 487258000 | ||
| Face value of equity share capital | 10 | ||
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | -0.38 | ||
| Diluted earnings (loss) per share from continuing operations | -0.38 | ||
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | ||
| Diluted earnings (loss) per share from discontinued operations | 0 | ||
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | -0.38 | ||
| Diluted earnings (loss) per share from continuing and discontinued operations | -0.38 | ||
| 24 | Debt equity ratio | 0.0047 | |
| 25 | Debt service coverage ratio | 0.0078 | |
| 26 | Interest service coverage ratio | 0.0026 | |
| 27 | Disclosure of notes on financial results | Textual Information(1) | |
Disclosure of notes on financial results |
|||
|---|---|---|---|
| Textual Information(1) | Notes The above unaudited consolidated financial of ZIM Laboratories Limited the Parent or the Company and its subsidiaries together referred to as Group were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 07 August 2025 The above results have been subjected to limited review by Statutory Auditor of the Parent 2 These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard Ind AS notified under the Companies Indian Accounting Standards Rules 2015 as amended as prescribed under Section 133 of the Companies Act 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India SEBI The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures for the year ended 31 March 2025 and the unaudited year to date figures upto 31 December 2024 4 The consolidated financial results of the Group for the quarter and year ended 31 March 2025 and quarter ended 30 June 2024 were reviewed audited by another auditor who expressed an unmodified conclusion/opinion on those results on 20 May 2025 and 03 August 2024 respectively 5 The Board of Directors of the Parent on 04 August 2025 have approved the closure of ZIM Laboratories Middle East DMCC Step Down Subsidiary subject to the approval of relevant regulatory authorities 6 The Group is principally engaged in a sigle business segment which is pharmaceuticals There is no seperate reportable segment as per Ind AS 108 Operating Segments nPlace Nagpur Anwar S. Daud nDate 07 August 2025 Managing Director | ||
Remarks |
|
|---|---|
| Debt equity ratio | |
| Debt service coverage ratio | |
| Interest service coverage ratio | |
Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results |
|||||||
|---|---|---|---|---|---|---|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
| Date of start of reporting period | 01-Apr-2025 | ||||||
| Date of end of reporting period | 30-Jun-2025 | ||||||
| Whether accounts are audited or unaudited | Unaudited | ||||||
| Nature of report standalone or consolidated | Consolidated | ||||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| Total Segment Revenue | |||||||
| Less: Inter segment revenue | |||||||
| Revenue from operations | |||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| Total Profit before tax | |||||||
| i. Finance cost | |||||||
| ii. Other Unallocable Expenditure net off Unallocable income | |||||||
| Profit before tax | |||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| Total Segment Asset | |||||||
| Un-allocable Assets | null | null | |||||
| Net Segment Asset | null | null | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| Total Segment Liabilities | |||||||
| Un-allocable Liabilities | null | null | |||||
| Net Segment Liabilities | null | null | |||||
| Disclosure of notes on segments | |||||||
Other Comprehensive Income |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Consolidated | |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| 1 | Measurements of defined employee benefit plans | -1899000 | -1899000 |
| Total Amount of items that will not be reclassified to profit and loss | -1899000 | ||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | -553000 | |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Gain and losses arising from translating the financial statements of foreign expenses | 5535000 | 5535000 |
| Total Amount of items that will be reclassified to profit and loss | 5535000 | ||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0 | |
| 5 | Total Other comprehensive income | 4189000 | |